Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Levofloxacin Versus Ceftriaxone for the Treatment of Acute Pyelonephritis in Iranian Adults

Author(s): Shabnam Tehrani, Fereshteh Elyasi and Sara Abolghasemi*

Volume 21, Issue 4, 2021

Published on: 27 July, 2020

Page: [603 - 607] Pages: 5

DOI: 10.2174/1871526520999200727154214

Price: $65

Abstract

Introduction: Acute pyelonephritis is among the most common bacterial infections. Options for initial treatment of pyelonephritis include an extended-spectrum cephalosporin or a fluoroquinolone. This study aimed to compare the clinical outcomes of patients receiving ceftriaxone to those who received levofloxacin for the treatment of acute pyelonephritis.

Methods: In this randomized, open-label trial, hospitalized adults with acute pyelonephritis were treated with ceftriaxone (1g IV every 12 hours) or levofloxacin (750 mg IV daily) for at least 7 days. Clinical and microbiological characteristics were compared among patients treated with ceftriaxone and levofloxacin.

Results: A total of 59 patients were randomized, 30 to the ceftriaxone group and 29 to the levofloxacin group. The clinical response was that 68.0% of patients in the ceftriaxone group and 56.0% of patients in the levofloxacin group were cured. The microbiological response, i.e. pathogen eradication rates was 68.7% in the ceftriaxone group and 21.4% in the levofloxacin group. (P value=0.00028) Escherichia coli was the most common pathogen (n = 31), followed by Klebsiella pneumoniae (n = 21). High resistance rates were detected for cotrimoxazole (55%), ciprofloxacin (48%), and ceftriaxone (34.4%) in isolated E.coli. Likewise, all K. pneumoniae isolates were resistant to ciprofloxacin.

Conclusion: This study indicates that ceftriaxone was more effective than levofloxacin in the treatment of acute pyelonephritis, on the basis of microbiological response, but there were no statistically significant differences between the treatment groups in the rates of clinical cure. The resistance of uropathogens to the most used antibiotics was relatively high. Choosing the treatment regimen based on susceptibility testing results and shortening the duration of the therapy are now recommended to be the most important approaches to decrease the spread of antibiotic resistance worldwide.

Keywords: Acute pyelonephritis, urinary tract infections, levofloxacin, ceftriaxone, Escherichia coli, K. pneumoniae.

[1]
Lichtenberger, P.; Hooton, T.M. Complicated urinary tract infections. Curr. Infect. Dis. Rep., 2008, 10(6), 499-504.
[http://dx.doi.org/10.1007/s11908-008-0081-0] [PMID: 18945392]
[2]
Ronald, A.R.; Nicolle, L.E.; Stamm, E.; Krieger, J.; Warren, J.; Schaeffer, A.; Naber, K.G.; Hooton, T.M.; Johnson, J.; Chambers, S.; Andriole, V. Urinary tract infection in adults: research priorities and strategies. Int. J. Antimicrob. Agents, 2001, 17(4), 343-348.
[http://dx.doi.org/10.1016/S0924-8579(01)00303-X] [PMID: 11295419]
[3]
Mazzulli, T. Diagnosis and management of simple and complicated urinary tract infections (UTIs). Can. J. Urol., 2012, 19(Suppl. 1), 42-48.
[PMID: 23089347]
[4]
Pallett, A.; Hand, K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J. Antimicrob. Chemother., 2010, 65(Suppl. 3), iii25-iii33.
[http://dx.doi.org/10.1093/jac/dkq298] [PMID: 20876625]
[5]
Acute Pyelonephritis in Adults. Acute Pyelonephritis in Adults. N. Engl. J. Med., 2018, 378(11), 1069.
[http://dx.doi.org/10.1056/NEJMx180009] [PMID: 29539281]
[6]
Efstathiou, S.P.; Pefanis, A.V.; Tsioulos, D.I.; Zacharos, I.D.; Tsiakou, A.G.; Mitromaras, A.G.; Mastorantonakis, S.E.; Kanavaki, S.N.; Mountokalakis, T.D. Acute pyelonephritis in adults: prediction of mortality and failure of treatment. Arch. Intern. Med., 2003, 163(10), 1206-1212.
[http://dx.doi.org/10.1001/archinte.163.10.1206] [PMID: 12767958]
[7]
Gupta, K.; Hooton, T.M.; Naber, K.G.; Wullt, B.; Colgan, R.; Miller, L.G.; Moran, G.J.; Nicolle, L.E.; Raz, R.; Schaeffer, A.J.; Soper, D.E. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis., 2011, 52(5), e103-e120.
[http://dx.doi.org/10.1093/cid/ciq257] [PMID: 21292654]
[8]
de Cueto, M.; Aliaga, L.; Alós, J.I.; Canut, A.; Los-Arcos, I.; Martínez, J.A.; Mensa, J.; Pintado, V.; Rodriguez-Pardo, D.; Yuste, J.R.; Pigrau, C. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm. Infecc. Microbiol. Clin., 2017, 35(5), 314-320.
[http://dx.doi.org/10.1016/j.eimc.2016.11.005] [PMID: 28017477]
[9]
Huang, E.S.; Stafford, R.S. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch. Intern. Med., 2002, 162(1), 41-47.
[http://dx.doi.org/10.1001/archinte.162.1.41] [PMID: 11784218]
[10]
Kahan, N.R.; Chinitz, D.P.; Kahan, E. Longer than recommended empiric antibiotic treatment of urinary tract infection in women: an avoidable waste of money. J. Clin. Pharm. Ther., 2004, 29(1), 59-63.
[http://dx.doi.org/10.1111/j.1365-2710.2003.00537.x] [PMID: 14748899]
[11]
Kallen, A.J.; Welch, H.G.; Sirovich, B.E. Current antibiotic therapy for isolated urinary tract infections in women. Arch. Intern. Med., 2006, 166(6), 635-639.
[http://dx.doi.org/10.1001/archinte.166.6.635] [PMID: 16567602]
[12]
Stamm, W.E. Evaluating guidelines. Clin. Infect. Dis., 2007, 44(6), 775-776.
[PMID: 17304446]
[13]
Assimakopoulos, S.F.; Kraniotis, P.; Gogos, C.; Marangos, M. Renal vein thrombosis complicating severe acute pyelonephritis with renal abscesses and associated bacteraemia caused by extended-spectrum beta-lactamase producing Escherichia coli. CEN Case Rep., 2018, 7(1), 90-93.
[http://dx.doi.org/10.1007/s13730-017-0301-2] [PMID: 29327131]
[14]
Livermore, D.M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother., 2009, 64(Suppl. 1), i29-i36.
[http://dx.doi.org/10.1093/jac/dkp255] [PMID: 19675016]
[15]
Mehrad, B.; Clark, N.M.; Zhanel, G.G.; Lynch, J.P., III Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest, 2015, 147(5), 1413-1421.
[http://dx.doi.org/10.1378/chest.14-2171] [PMID: 25940252]
[16]
Bouchillon, S.; Hoban, D.J.; Badal, R.; Hawser, S. Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010. Open Microbiol. J., 2012, 6, 74-78.
[http://dx.doi.org/10.2174/1874285801206010074] [PMID: 23002406]
[17]
Park, S.H. Third-generation cephalosporin resistance in gram-negative bacteria in the community: a growing public health concern. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.), 2014, 29(1), 27-30.
[http://dx.doi.org/10.3904/kjim.2014.29.1.27] [PMID: 24574830]
[18]
McGregor, J.C.; Allen, G.P.; Bearden, D.T. Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Ther. Clin. Risk Manag., 2008, 4(5), 843-853.
[http://dx.doi.org/10.2147/TCRM.S3426] [PMID: 19209267]
[19]
Park, D.W.; Peck, K.R.; Chung, M.H.; Lee, J.S.; Park, Y.S.; Kim, H.Y.; Lee, M.S.; Kim, J.Y.; Yeom, J.S.; Kim, M.J. Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial. J. Korean Med. Sci., 2012, 27(5), 476-483.
[http://dx.doi.org/10.3346/jkms.2012.27.5.476] [PMID: 22563210]
[20]
Wells, W.G. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J. Antimicrob. Chemother., 2004, 53(suppl_2), ii67-ii74.
[http://dx.doi.org/10.1093/jac/dkh208]
[21]
Jeon, J.H.; Kim, K.; Han, W.D.; Song, S.H.; Park, K.U.; Rhee, J.E.; Song, K.H.; Park, W.B.; Kim, E.S.; Park, S.W.; Kim, N.J.; Oh, M.D.; Kim, H.B. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob. Agents Chemother., 2012, 56(6), 3043-3046.
[http://dx.doi.org/10.1128/AAC.06212-11] [PMID: 22391544]
[22]
CLSI. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. M100-S24, 2014 January;
[23]
Ramakrishnan, K.; Scheid, D.C. Diagnosis and management of acute pyelonephritis in adults. Am. Fam. Physician, 2005, 71(5), 933-942.
[PMID: 15768623]
[24]
Tayebi, Z.; Heidari, H.; Kazemian, H.; Ghafoori, S.M.; Boroumandi, S.; Houri, H. Comparison of quinolone and beta-lactam resistance among Escherichia coli strains isolated from urinary tract infections. Infez. Med., 2016, 24(4), 326-330.
[PMID: 28011969]
[25]
Poursina, F.; Sepehrpour, S.; Mobasherizadeh, S. Biofilm Formation in Nonmultidrug-resistant Escherichia coli Isolated from Patients with Urinary Tract Infection in Isfahan, Iran. Adv. Biomed. Res., 2018, 7, 40.
[http://dx.doi.org/10.4103/abr.abr_116_17] [PMID: 29657925]
[26]
Lin, H-A.; Yang, Y.S.; Wang, J.X.; Lin, H.C.; Lin, D.Y.; Chiu, C.H.; Yeh, K.M.; Lin, J.C.; Chang, F.Y. Comparison of the effectiveness and antibiotic cost among ceftriaxone, ertapenem, and levofloxacin in treatment of community-acquired complicated urinary tract infections. J. Microbiol. Immunol. Infect., 2016, 49(2), 237-242.
[http://dx.doi.org/10.1016/j.jmii.2014.12.010] [PMID: 25661278]
[27]
Nix, D.E. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. Journal of Antimicrobial Chemotherapy, 2004, 53(suppl_2), ii23-ii28..
[http://dx.doi.org/10.1093/jac/dkh205]
[28]
Perry, T.R.; Schentag, J.J. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin. Pharmacokinet., 2001, 40(9), 685-694.
[http://dx.doi.org/10.2165/00003088-200140090-00004] [PMID: 11605716]
[29]
Deguchi, T.; Nakane, K.; Yasuda, M.; Shimizu, T.; Monden, K.; Arakawa, S.; Matsumoto, T. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. Int. J. Antimicrob. Agents, 2010, 35(6), 573-577.
[http://dx.doi.org/10.1016/j.ijantimicag.2010.02.004] [PMID: 20226636]
[30]
Nicolle, L.; Duckworth, H.; Sitar, D.; Bryski, L.; Harding, G.; Zhanel, G. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. Int. J. Antimicrob. Agents, 2008, 31(3), 287-289.
[http://dx.doi.org/10.1016/j.ijantimicag.2007.10.021] [PMID: 18155885]
[31]
Leylabadlo, H.E.; Pourlak, T.; Bialvaei, A.Z.; Aghazadeh, M.; Asgharzadeh, M.; Kafil, H.S. Extended-spectrum beta-lactamase producing gram negative bacteria in iran: A review. Afr. J. Infect. Dis., 2017, 11(2), 39-53.
[http://dx.doi.org/10.21010/ajid.v11i2.6] [PMID: 28670639]
[32]
Rezai, M.S.; Salehifar, E.; Rafiei, A.; Langaee, T.; Rafati, M.; Shafahi, K.; Eslami, G. Characterization of multidrug resistant extended-spectrum beta-lactamase-producing escherichia coli among uropathogens of pediatrics in north of Iran. BioMed. Res. Int., 2015, 2015, 309478.
[http://dx.doi.org/10.1155/2015/309478] [PMID: 26064896]
[33]
Pouladfar, G.; Basiratnia, M.; Anvarinejad, M.; Abbasi, P.; Amirmoezi, F.; Zare, S. The antibiotic susceptibility patterns of uropathogens among children with urinary tract infection in Shiraz. Medicine (Baltimore), 2017, 96(37), e7834.
[http://dx.doi.org/10.1097/MD.0000000000007834] [PMID: 28906365]
[34]
Giani, T.; Antonelli, A.; Caltagirone, M.; Mauri, C.; Nicchi, J.; Arena, F.; Nucleo, E.; Bracco, S.; Pantosti, A.; Luzzaro, F.; Pagani, L.; Rossolini, G.M. AMCLI-CoSA survey participants. Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. Euro Surveill., 2017, 22(31), 30583.
[http://dx.doi.org/10.2807/1560-7917.ES.2017.22.31.30583] [PMID: 28797330]

Rights & Permissions Print Cite
Article Metrics
60
1
© 2024 Bentham Science Publishers | Privacy Policy